2BB score and signals
Summit Therapeutics Inc.’s current 2BB score is 60 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 72 | High |
| Momentum | 68 | Improving |
| Financial strength | 41 | Normal |
| Quality | 98 | Very Strong |
| Risk | 32 | Low |
Company facts
| Founded | Aug 4, 2004 |
| Employees | 61 |
| 52-week range | $12.07 – $29.23 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-22 | — | -0.3683 | — | $3.78M |
| 2026-10-19 | — | -0.2959 | — | $68,003.00 |
| 2026-07-23 | — | -0.2849 | — | $0.00 |
| 2026-04-30 | -0.24 | -0.1801 | $0.00 | $72,114.00 |
Related companies
